Canada’s biotech carpe diem
It’s imperative Canada keep pace with other competing jurisdictions, and establish itself as a regulatory leader that rewards investment and talent.
The pandemic’s economic, social, and health impacts have effectively focused the attention of policymakers and the public on the strategic importance of building a competitive domestic life sciences industry and biomanufacturing capacity. Accordingly, nearly four years aft...
SPONSORED CONTENT
Get Tuesdays: Innovation & Industry Newsletter
The policies, decisions, and people working on investment and regulation in the industry and innovation realm.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
